The U.S. Food and Drug Administration (FDA) has approved a cell-based gene therapy known as lisocabtagene maraleucel (brand name Breyanzi) for relapsed or refractory large B-cell lymphoma.
.
The U.S. Food and Drug Administration (FDA) has approved a cell-based gene therapy known as lisocabtagene maraleucel (brand name Breyanzi) for relapsed or refractory large B-cell lymphoma.
.